| Today’s Big NewsOct 31, 2023 |
| By Zoey Becker With Pfizer's established franchises and its RSV vaccine Arbysvo, the former COVID-19 king is looking to overcome a steep decline for its pandemic-related business. |
|
|
|
By Annalee Armstrong Sanofi is making an initial $30 million investment in MeiraGTx to gain a first peek at data from the biotech’s riboswitch platform, all for a chance to someday brew up some new deals. |
By Conor Hale Olympus has told healthcare providers to stop using its insufflation hardware for laparoscopic surgery until further notice, while it examines reports of over-inflation. |
By Angus Liu As several new JAK inhibitors threaten Incyte’s bread-and-butter Jakafi in myelofibrosis, the company is busy advancing new regimens ahead of the drug’s 2028 patent cliff. |
|
Thursday, November 9, 2023 | 11am ET / 8am PT Navigating the U.S. regulatory landscape for the use of high-purity alcohols in biologic development and manufacturing processes is crucial for maintaining product quality and patient safety. However, biomanufacturers often face significant challenges. Join us to gain key guidance from industry experts and learn important best practices. Register now.
|
|
By Gabrielle Masson In a year riddled with obstacles and adverse events, Mersana Therapeutics finally has some good news: The FDA has lifted a clinical hold on a phase 1 trial for the antibody-drug conjugate XMT-2056. |
By Conor Hale Access Vascular hopes to take a bite out of the infections and complications that can come with delivering intravenous therapies, which can cost health systems as much as $4.5 billion per year. |
By Kevin Dunleavy For 50 million euros plus potential milestones of 120 million euros, Galapagos agreed to transfer its Jyseleca marketing authorizations and support staff to Alfasigma. Galapagos will cut another 100 jobs as part of its streamlining efforts. |
By Annalee Armstrong Arrowhead Pharmaceuticals finally knows the future of its hepatitis B med: Johnson & Johnson has offloaded the rights to GSK. |
By Gabrielle Masson With a confirmatory trial for Sarepta’s Duchenne muscular dystrophy trial ending in failure, Pfizer’s chief scientist says the pharma giant’s gene therapy is now “the main game in town.” |
Fierce podcastsDon’t miss an episode |
| In this episode of “The Top Line,” we delve into the FDA's controversial approval of Aduhelm, a drug for Alzheimer's disease, despite an independent advisory committee's resounding rejection. The decision has sparked questions about potential bias within the regulatory body. |
|
|---|
|
|
|
Thursday, November 16, 2023 | 1pm ET / 10am PT Genomics is transforming drug discovery, but finding and recruiting the right patients for targeted-therapies remains a challenge. Join us to discover how incorporating genetic counseling and genetic services can unlock larger, more diverse and better qualified patient populations for your clinical trials. Register now.
|
|
| WebinarEmbark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
| WhitepaperEconomic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| WhitepaperUncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
| WhitepaperFrom Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
| |
|
